{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T22:26:49Z","timestamp":1749853609505,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Faecal microbial transplantation (FMT) is currently the most effective treatment of recurrent <jats:italic>Clostridioides difficile<\/jats:italic> infection (CDI). However, up to 20% of patients experience further recurrences after single FMT. The mechanisms that lead to FMT failure and its risk factors are poorly understood. Comorbidity is one of the risk factors of the failure of standard antibiotic therapy of recurrent CDI. It is not known if comorbidity is also associated with the risk of FMT failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a prospective observational cohort study in order to elucidate if comorbid status is associated with FMT failure. Patients with microbiologically proven recurrent CDI were recruited and underwent FMT via retention enema. Patients were followed up for 12\u2009weeks after FMT for signs and symptoms of CDI recurrence. Single FMT failure was defined as recurrence of diarrhoea and a positive stool test for the presence of <jats:italic>C. difficile<\/jats:italic> antigen or toxin at any time point during the 12\u2009weeks of follow-up. We assessed the association of single FMT failure with possible manageable and unmanageable risk factors. As a surrogate of comorbid status, we used Charlson Comorbidity Index (CCI)\u2009\u2265\u20097.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 60 patients that underwent single FMT (34 women, 26 men) were included in the study. Overall, 15 patients (25%) experienced single FMT failure. 24 patients (40%) had CCI\u2009\u2265\u20097, and 45.0% patients with CCI\u2009\u2265\u20097 experienced failure of single FMT. Patients who experienced single FMT failure had a significantly higher CCI and significantly lower albumin concentration as compared to patients who experienced single FMT success. There was no difference in age, C-reactive protein concentration, leukocyte count and time from FMT to first defecation. In multivariate analysis, CCI\u2009\u2265\u20097 was positively associated with the failure of single FMT. Analysis was controlled for sex, age, time from FMT to first defecation, concomitant PPI therapy, severe CDI, hospital-acquired infection and albumin concentration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Comorbid status surrogated by CCI is positively associated with the failure of single FMT in the treatment of recurrent CDI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-020-4773-x","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T15:03:27Z","timestamp":1579187007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comorbid status and the faecal microbial transplantation failure in treatment of recurrent Clostridioides difficile infection \u2013 pilot prospective observational cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"M.","family":"Kachl\u00edkov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9337-8843","authenticated-orcid":false,"given":"P.","family":"Sabaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ko\u0161\u010d\u00e1lov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bend\u017eala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Dovalov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Stankovi\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"key":"4773_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.anaerobe.2016.06.008","volume":"40","author":"PA Lawson","year":"2016","unstructured":"Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Pr\u00e9vot 1938. Anaerobe. 2016;40:95\u20139. https:\/\/doi.org\/10.1016\/j.anaerobe.2016.06.008 Epub 2016 Jun 28.","journal-title":"Anaerobe."},{"key":"4773_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13017-019-0228-3","volume":"14","author":"M Sartelli","year":"2019","unstructured":"Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019;14:8.","journal-title":"World J Emerg Surg"},{"key":"4773_CR3","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1056\/NEJMc1505190","volume":"372","author":"FC Lessa","year":"2015","unstructured":"Lessa FC, Winston LG, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:2369\u201370. https:\/\/doi.org\/10.1056\/NEJMc1505190.","journal-title":"N Engl J Med"},{"key":"4773_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2012.02.004","volume":"81","author":"PN Wiegand","year":"2012","unstructured":"Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81:1\u201314. https:\/\/doi.org\/10.1016\/j.jhin.2012.02.004.","journal-title":"J Hosp Infect."},{"key":"4773_CR5","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/cid\/cis1209","volume":"56","author":"MP Hensgens","year":"2013","unstructured":"Hensgens MP, Goorhuis A, Dekkers OM, van Benthem BH, Kuijper EJ. All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis. 2013;56:1108\u201316. https:\/\/doi.org\/10.1093\/cid\/cis1209.","journal-title":"Clin Infect Dis"},{"key":"4773_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jhin.2016.04.004","volume":"93","author":"DN Shah","year":"2016","unstructured":"Shah DN, Aitken SL, Barragan LF, Bozorgui S, Goddu S, Navarro ME, et al. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016;93:286\u20139. https:\/\/doi.org\/10.1016\/j.jhin.2016.04.004.","journal-title":"J Hosp Infect."},{"key":"4773_CR7","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1001\/jama.1994.03510480037031","volume":"271","author":"LV McFarland","year":"1994","unstructured":"McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913\u20138.","journal-title":"JAMA."},{"key":"4773_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jhin.2008.08.012","volume":"70","author":"KW Garey","year":"2008","unstructured":"Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298\u2013304.","journal-title":"J Hosp Infect"},{"key":"4773_CR9","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1128\/JCM.38.6.2386-2388.2000","volume":"38","author":"F Barbut","year":"2000","unstructured":"Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38:2386\u20138.","journal-title":"J Clin Microbiol"},{"key":"4773_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.anaerobe.2017.03.003","volume":"44","author":"N Khanafer","year":"2017","unstructured":"Khanafer N, Vanhems P, Barbut F, Luxemburger C. Factors associated with Clostridium difficile infection: a nested case-control study in a three year prospective cohort. Anaerobe. 2017;44:117\u201323. https:\/\/doi.org\/10.1016\/j.anaerobe.2017.03.003.","journal-title":"Anaerobe."},{"issue":"Suppl 2","key":"4773_CR11","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1093\/cid\/civ140","volume":"60","author":"CT Evans","year":"2015","unstructured":"Evans CT, Safdar N. Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clin Infect Dis. 2015;60(Suppl 2):S66\u201371. https:\/\/doi.org\/10.1093\/cid\/civ140.","journal-title":"Clin Infect Dis"},{"key":"4773_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajic.2010.08.017","volume":"39","author":"R Shakov","year":"2011","unstructured":"Shakov R, Salazar RS, Kagunye SK, Baddoura WJ, DeBari VA. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control. 2011;39:194\u20138. https:\/\/doi.org\/10.1016\/j.ajic.2010.08.017.","journal-title":"Am J Infect Control"},{"key":"4773_CR13","first-page":"609","volume":"12","author":"LS Al-Jashaami","year":"2016","unstructured":"Al-Jashaami LS, DuPont HL. Management of Clostridium difficile infection. Gastroenterol Hepatol (N Y). 2016;12:609\u201316.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"4773_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4103\/jgid.jgid_145_17","volume":"10","author":"R Duarte-Chavez","year":"2018","unstructured":"Duarte-Chavez R, Wojda TR, Zanders TB, Geme B, Fioravanti G, Stawicki SP. Single results of fecal microbial transplantation protocol implementation at a community-based university hospital. J Glob Infect Dis. 2018;10:47\u201357.","journal-title":"J Glob Infect Dis"},{"key":"4773_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/apt.14201","volume":"46","author":"MN Quraishi","year":"2017","unstructured":"Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46:479\u201393. https:\/\/doi.org\/10.1111\/apt.14201.","journal-title":"Aliment Pharmacol Ther"},{"key":"4773_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/antibiotics4030230","volume":"4","author":"C Vincent","year":"2015","unstructured":"Vincent C, Manges AR. Antimicrobial use, human gut microbiota and Clostridium difficile colonization and infection. Antibiotics (Basel). 2015;4:230\u201353. https:\/\/doi.org\/10.3390\/antibiotics4030230.","journal-title":"Antibiotics (Basel)"},{"key":"4773_CR17","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/cid\/cix511","volume":"65","author":"RL Patron","year":"2017","unstructured":"Patron RL, Hartmann CA, Allen S, Griesbach CL, Kosiorek HE, DiBaise JK, et al. Vancomycin taper and risk of failure of fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. Clin Infect Dis. 2017;65:1214\u20137. https:\/\/doi.org\/10.1093\/cid\/cix511.","journal-title":"Clin Infect Dis"},{"key":"4773_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/MEG.0000000000000614","volume":"28","author":"A Meighani","year":"2016","unstructured":"Meighani A, Hart BR, Mittal C, Miller N, John A, Ramesh M. Predictors of fecal transplant failure. Eur J Gastroenterol Hepatol. 2016;28:826\u201330. https:\/\/doi.org\/10.1097\/MEG.0000000000000614.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4773_CR19","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/ajg.2016.180","volume":"111","author":"M Fischer","year":"2016","unstructured":"Fischer M, Kao D, Mehta SR, Martin T, Dimitry J, Keshteli AH, et al. Predictors of single failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol. 2016;111:1024\u201331. https:\/\/doi.org\/10.1038\/ajg.2016.180.","journal-title":"Am J Gastroenterol"},{"key":"4773_CR20","doi-asserted-by":"publisher","first-page":"e4973","DOI":"10.1097\/MD.0000000000004973","volume":"95","author":"P Fraccaro","year":"2016","unstructured":"Fraccaro P, Kontopantelis E, Sperrin M, Peek N, Mallen C, Urban P, et al. Predicting mortality from change-over-time in the Charlson Comorbidity Index: a retrospective cohort study in a data-intensive UK health system. Medicine (Baltimore). 2016;95:e4973.","journal-title":"Medicine (Baltimore)"},{"key":"4773_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jphys.2016.05.008","volume":"62","author":"CE Roffman","year":"2016","unstructured":"Roffman CE, Buchanan J, Allison GT. Charlson comorbidities index. J Physiother. 2016;62:171. https:\/\/doi.org\/10.1016\/j.jphys.2016.05.008.","journal-title":"J Physiother"},{"key":"4773_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-2407-4-94","volume":"4","author":"WH Hall","year":"2004","unstructured":"Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004;4:94. https:\/\/doi.org\/10.1186\/1471-2407-4-94.","journal-title":"BMC Cancer"},{"issue":"Suppl 4","key":"4773_CR23","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.cmi.2016.03.010","volume":"22","author":"MJ Crobach","year":"2016","unstructured":"Crobach MJ, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(Suppl 4):S63\u201381. https:\/\/doi.org\/10.1016\/j.cmi.2016.03.010 Epub 2016 Jul 25.","journal-title":"Clin Microbiol Infect"},{"key":"4773_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmi.2017.07.025","volume":"24","author":"YH van Beurden","year":"2018","unstructured":"van Beurden YH, Nezami S, Mulder CJJ, Vandenbroucke-Grauls CMJE. Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics. Clin Microbiol Infect. 2018;24:85.e1\u201385.e4. https:\/\/doi.org\/10.1016\/j.cmi.2017.07.025.","journal-title":"Clin Microbiol Infect"},{"key":"4773_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00508-018-1432-y","volume":"131","author":"D Knafl","year":"2019","unstructured":"Knafl D, Vossen MG, Gerges C, Lobmeyr E, Karolyi M, Wagner L, et al. Hypoalbuminemia as predictor of recurrence of Clostridium difficile infection. Wien Klin Wochenschr. 2019;131:68\u201374. https:\/\/doi.org\/10.1007\/s00508-018-1432-y.","journal-title":"Wien Klin Wochenschr"},{"key":"4773_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1177\/2050640617750809","volume":"6","author":"NA Cohen","year":"2017","unstructured":"Cohen NA, Miller T, Na'aminh W, Hod K, Adler A, Cohen D, et al. Clostridium difficile fecal toxin level is associated with disease severity and prognosis. United European Gastroenterol J. 2017;6:773\u201380. https:\/\/doi.org\/10.1177\/2050640617750809.","journal-title":"United European Gastroenterol J"},{"key":"4773_CR27","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s11605-012-2037-9","volume":"16","author":"A Rotramel","year":"2012","unstructured":"Rotramel A, Poritz LS, Messaris E, Berg A, Stewart DB. PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics. J Gastrointest Surg. 2012;16:2267\u201373. https:\/\/doi.org\/10.1007\/s11605-012-2037-9.","journal-title":"J Gastrointest Surg"},{"key":"4773_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/MCG.0000000000000410","volume":"50","author":"M Agrawal","year":"2016","unstructured":"Agrawal M, Aroniadis OC, Brandt LJ, Kelly C, Freeman S, Surawicz C, et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol. 2016;50:403\u20137. https:\/\/doi.org\/10.1097\/MCG.0000000000000410.","journal-title":"J Clin Gastroenterol"},{"issue":"Suppl 1","key":"4773_CR29","doi-asserted-by":"publisher","first-page":"S336","DOI":"10.1093\/ofid\/ofy210.955","volume":"5","author":"A Hassoun","year":"2018","unstructured":"Hassoun A, Edwards J. Evaluation of fecal microbiota transplant (FMT) in elderly patients with recurrent Clostridium difficile infection (CDI). Open Forum Infect Dis. 2018;5(Suppl 1):S336. https:\/\/doi.org\/10.1093\/ofid\/ofy210.955.","journal-title":"Open Forum Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-4773-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:09:47Z","timestamp":1610669387000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-4773-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4773"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-4773-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2020,1,16]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was carried out in concordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans and was approved by the local Ethical Committee of University Hospital Bratislava. The participants signed informed consent. The investigators preserved full anonymity of all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}